Zacks: Brokerages Anticipate Protagonist Therapeutics Inc (NASDAQ:PTGX) Will Announce Quarterly Sales of $5.25 Million

Share on StockTwits

Brokerages expect Protagonist Therapeutics Inc (NASDAQ:PTGX) to post sales of $5.25 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Protagonist Therapeutics’ earnings. The highest sales estimate is $5.50 million and the lowest is $5.00 million. Protagonist Therapeutics posted sales of $2.35 million in the same quarter last year, which suggests a positive year-over-year growth rate of 123.4%. The business is expected to announce its next quarterly earnings report on Tuesday, March 10th.

On average, analysts expect that Protagonist Therapeutics will report full year sales of $4.81 million for the current year, with estimates ranging from $2.51 million to $8.90 million. For the next fiscal year, analysts forecast that the business will post sales of $18.00 million, with estimates ranging from $16.00 million to $20.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.61) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.10. The business had revenue of $4.14 million during the quarter, compared to the consensus estimate of $5.75 million. Protagonist Therapeutics had a negative return on equity of 74.86% and a negative net margin of 209.02%.

A number of research firms recently weighed in on PTGX. ValuEngine downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. BidaskClub cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 9th. Zacks Investment Research raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, November 19th. Svb Leerink reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research report on Tuesday, August 13th. Finally, Nomura reaffirmed a “buy” rating and set a $29.00 price target on shares of Protagonist Therapeutics in a research report on Sunday, August 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $19.60.

NASDAQ PTGX opened at $8.85 on Tuesday. The company has a market capitalization of $236.70 million, a price-to-earnings ratio of -5.09 and a beta of 1.52. Protagonist Therapeutics has a twelve month low of $6.18 and a twelve month high of $16.67. The stock has a fifty day simple moving average of $10.94 and a 200 day simple moving average of $11.82. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 0.07.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers boosted its position in Protagonist Therapeutics by 20.7% during the third quarter. Rhumbline Advisers now owns 15,540 shares of the company’s stock valued at $187,000 after acquiring an additional 2,662 shares during the last quarter. California State Teachers Retirement System boosted its position in Protagonist Therapeutics by 13.7% during the third quarter. California State Teachers Retirement System now owns 26,542 shares of the company’s stock valued at $319,000 after acquiring an additional 3,195 shares during the last quarter. Meeder Asset Management Inc. boosted its position in Protagonist Therapeutics by 1,433.3% during the third quarter. Meeder Asset Management Inc. now owns 3,450 shares of the company’s stock valued at $41,000 after acquiring an additional 3,225 shares during the last quarter. Wells Fargo & Company MN boosted its position in Protagonist Therapeutics by 25.9% during the second quarter. Wells Fargo & Company MN now owns 20,553 shares of the company’s stock valued at $248,000 after acquiring an additional 4,224 shares during the last quarter. Finally, Algert Global LLC boosted its position in Protagonist Therapeutics by 48.0% during the second quarter. Algert Global LLC now owns 15,517 shares of the company’s stock valued at $188,000 after acquiring an additional 5,030 shares during the last quarter. 69.62% of the stock is currently owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

See Also: Economic Reports

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.